<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">Among all subjects in Stratum 1 who received DFMO, the two-year EFS was 84% ± 4% and OS was 97% ± 2% (Fig. 
 <xref rid="Fig2" ref-type="fig">2a,b</xref>). The median follow-up time is 3.5 years (range 2.1–5.8 years). EFS and OS were similarly high regardless of high risk features, including 
 <italic>MYCN</italic> status (Table 
 <xref rid="Tab1" ref-type="table">1</xref>, Fig. 
 <xref rid="Fig2" ref-type="fig">2c,d</xref>). The subset of subjects that received DFMO following completion of the COG ch14:18 antibody clinical trial (ANBL0032, n = 81) had a 2-year EFS of 86% ± 4%, (Fig. 
 <xref rid="Fig2" ref-type="fig">2e</xref>) and OS of 97% ± 2% (Fig. 
 <xref rid="Fig2" ref-type="fig">2f</xref>).
</p>
